Drugs / Sr-89
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05466812 | Jul 2022 → Jul 2024 | metastatic carcinoma in the bone, thyroid gland follicular carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sr-89 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05466812 ↗ |